Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Janux Therapeutics (JANX) Financials

Janux Therapeutics logo
$24.70 -0.83 (-3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$24.71 +0.01 (+0.04%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Janux Therapeutics

Annual Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -8.73 -33 -63 -58 -69
Consolidated Net Income / (Loss)		 -6.78 -33 -63 -58 -69
Net Income / (Loss) Continuing Operations		 -8.73 -33 -63 -58 -69
Total Pre-Tax Income 		-8.73 -33 -63 -58 -69
Total Operating Income		 -4.84 -33 -67 -73 -99
Total Gross Profit		 0.00 3.64 8.61 8.08 11
Total Revenue		 0.00 3.64 8.61 8.08 11
Operating Revenue		 0.00 3.64 8.61 8.08 11
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.84 37 76 81 109
Selling, General & Admin Expense		 1.80 10 22 26 41
Research & Development Expense		 3.04 26 53 55 68
Total Other Income / (Expense), net		 -3.88 0.26 4.03 15 30
Interest & Investment Income		 0.00 0.26 4.03 15 30
Basic Earnings per Share		 ($7.41) ($1.39) ($1.52) ($1.32) ($1.28)
Weighted Average Basic Shares Outstanding		 915.15K 23.53M 41.47M 44.02M 53.75M
Diluted Earnings per Share		 ($7.41) ($1.39) ($1.52) ($1.32) ($1.28)
Weighted Average Diluted Shares Outstanding		 915.15K 23.53M 41.47M 44.02M 53.75M
Weighted Average Basic & Diluted Shares Outstanding		 915.15K 23.53M 41.83M 51.66M 59.11M

Quarterly Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Consolidated Net Income / (Loss)		 -17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Net Income / (Loss) Continuing Operations		 -17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Total Pre-Tax Income 		-17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Total Operating Income		 -18 -18 -20 -21 -16 -16 -20 -14 -36 -29 -35
Total Gross Profit		 1.81 2.85 2.05 1.06 2.52 2.46 1.25 8.90 0.44 - 0.00
Total Revenue		 1.81 2.85 2.05 1.06 2.52 2.46 1.25 8.90 0.44 - 0.00
Operating Revenue		 1.81 2.85 2.05 1.06 2.52 2.46 1.25 8.90 0.44 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 20 21 22 22 18 19 21 23 36 29 35
Selling, General & Admin Expense		 6.10 5.68 6.46 6.88 6.44 6.36 7.34 7.82 18 8.22 9.84
Research & Development Expense		 14 15 16 15 12 12 14 15 19 21 25
Total Other Income / (Expense), net		 1.33 2.07 2.82 3.24 4.25 4.38 5.40 7.86 7.78 8.81 11
Interest & Investment Income		 1.33 2.20 2.82 3.24 4.25 4.38 5.40 7.86 7.78 8.81 11
Basic Earnings per Share		 ($0.40) ($0.39) ($0.42) ($0.42) ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38)
Weighted Average Basic Shares Outstanding		 41.53M 41.47M 41.76M 41.84M 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M
Diluted Earnings per Share		 ($0.40) ($0.39) ($0.42) ($0.42) ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38)
Weighted Average Diluted Shares Outstanding		 41.53M 41.47M 41.76M 41.84M 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M
Weighted Average Basic & Diluted Shares Outstanding		 41.66M 41.83M 41.83M 46.14M 46.17M 51.66M 51.85M 52.16M 52.48M 59.11M 59.18M

Annual Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 7.16 29 16 -32 411
Net Cash From Operating Activities		 -4.37 -17 -43 -51 -44
Net Cash From Continuing Operating Activities		 -4.37 -17 -43 -51 -44
Net Income / (Loss) Continuing Operations		 -6.78 -33 -63 -58 -69
Consolidated Net Income / (Loss)		 -6.78 -33 -63 -58 -69
Depreciation Expense		 0.01 0.11 0.84 1.96 2.06
Amortization Expense		 0.00 -0.17 -2.18 -7.69 -11
Non-Cash Adjustments To Reconcile Net Income		 2.01 6.91 17 20 33
Changes in Operating Assets and Liabilities, net		 0.39 8.84 4.28 -6.55 0.69
Net Cash From Investing Activities		 0.00 -341 58 -41 -258
Net Cash From Continuing Investing Activities		 0.00 -341 58 -41 -258
Purchase of Property, Plant & Equipment		 0.00 -1.48 -6.45 -1.85 -0.36
Purchase of Investments		 0.00 -474 -294 -317 -471
Sale and/or Maturity of Investments		 0.00 134 359 278 213
Net Cash From Financing Activities		 12 387 0.50 60 713
Net Cash From Continuing Financing Activities		 12 387 0.50 60 713
Issuance of Common Equity		 0.00 204 0.00 57 698
Other Financing Activities, net		 0.07 1.81 0.50 3.02 15

Quarterly Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 6.35 -13 -21 3.35 -17 2.05 194 -198 12 404 -357
Net Cash From Operating Activities		 -13 -12 -14 -15 -12 -9.90 -15 -10 -2.23 -17 -17
Net Cash From Continuing Operating Activities		 -13 -12 -14 -15 -12 -9.90 -15 -10 -2.23 -17 -17
Net Income / (Loss) Continuing Operations		 -17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Consolidated Net Income / (Loss)		 -17 -16 -17 -18 -12 -12 -15 -5.96 -28 -20 -24
Depreciation Expense		 0.25 0.40 0.45 0.47 0.50 0.53 0.53 0.51 0.51 0.51 0.52
Amortization Expense		 -0.77 -1.29 -1.68 -1.84 -2.11 -2.06 -1.79 -2.97 -2.90 -2.93 -4.22
Non-Cash Adjustments To Reconcile Net Income		 4.60 4.21 5.47 5.50 4.55 4.48 5.63 5.76 15 6.25 11
Changes in Operating Assets and Liabilities, net		 -0.80 0.84 -0.70 -1.68 -3.08 -1.10 -4.45 -7.35 13 -0.35 -0.52
Net Cash From Investing Activities		 20 -1.60 -8.74 18 -61 11 -114 -191 13 34 -340
Net Cash From Continuing Investing Activities		 20 -1.60 -8.74 18 -61 11 -114 -191 13 34 -340
Purchase of Property, Plant & Equipment		 -2.52 -2.06 -0.29 -0.58 -0.47 -0.52 -0.20 -0.10 -0.03 -0.04 -0.37
Purchase of Investments		 -94 -86 -72 -77 -136 -33 -179 -236 -32 -24 -371
Sale and/or Maturity of Investments		 117 87 63 95 75 45 65 45 45 58 31
Net Cash From Financing Activities		 - 0.19 1.58 0.53 57 0.83 322 2.77 1.65 387 0.55
Net Cash From Continuing Financing Activities		 - 0.19 1.58 0.53 57 0.83 322 2.77 1.65 387 0.55
Issuance of Common Equity		 - - 0.00 - 57 - 321 -0.46 - 378 -0.35
Other Financing Activities, net		 - 0.19 1.58 0.53 0.08 0.83 1.66 3.22 1.65 8.44 0.90

Annual Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 16 380 364 380 1,062
Total Current Assets		 16 377 332 349 1,034
Cash & Equivalents		 7.81 36 51 19 431
Short-Term Investments		 0.00 339 276 325 595
Prepaid Expenses		 0.25 2.05 5.42 5.21 8.49
Plant, Property, & Equipment, net		 0.16 1.41 7.09 7.00 4.86
Total Noncurrent Assets		 0.00 1.39 24 24 23
Other Noncurrent Operating Assets		 0.00 1.39 24 24 23
Total Liabilities & Shareholders' Equity		 16 380 364 380 1,062
Total Liabilities		 9.23 13 43 36 39
Total Current Liabilities		 3.18 13 17 13 17
Accounts Payable		 0.43 2.46 2.16 2.42 4.03
Accrued Expenses		 0.75 3.78 8.18 7.39 12
Current Deferred Revenue		 1.95 5.16 5.41 1.71 0.00
Other Current Liabilities		 0.05 1.40 0.76 1.52 1.75
Total Noncurrent Liabilities		 6.05 0.70 27 23 21
Noncurrent Deferred Revenue		 6.05 0.70 2.22 0.00 0.00
Other Noncurrent Operating Liabilities		 - 0.00 25 23 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 366 321 344 1,023
Total Preferred & Common Equity		 -15 366 321 344 1,023
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -15 366 321 344 1,023
Common Stock		 0.10 414 433 512 1,258
Retained Earnings		 -15 -47 -110 -169 -238
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.27 -1.54 0.67 2.16

Quarterly Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 376 353 342 387 689 691 695 1,051
Total Current Assets		 344 321 309 355 659 662 666 1,023
Cash & Equivalents		 65 30 34 17 213 15 27 74
Short-Term Investments		 274 287 270 333 439 632 631 940
Prepaid Expenses		 5.07 3.77 6.01 5.48 6.38 8.15 8.29 9.19
Plant, Property, & Equipment, net		 6.51 7.20 7.38 7.32 6.52 5.94 5.37 4.95
Total Noncurrent Assets		 25 24 25 24 24 24 23 22
Other Noncurrent Operating Assets		 25 24 25 24 24 24 23 22
Total Liabilities & Shareholders' Equity		 376 353 342 387 689 691 695 1,051
Total Liabilities		 44 42 42 38 33 34 39 38
Total Current Liabilities		 16 16 18 14 11 12 17 18
Accounts Payable		 2.87 2.05 1.91 2.51 2.25 1.25 2.46 2.35
Accrued Expenses		 7.24 7.74 9.22 6.83 5.81 8.57 13 13
Current Deferred Revenue		 5.91 4.94 5.34 3.65 0.97 0.09 0.00 0.00
Other Current Liabilities		 0.32 1.39 1.44 1.49 1.57 1.63 1.69 1.81
Total Noncurrent Liabilities		 28 26 24 23 23 22 22 21
Noncurrent Deferred Revenue		 3.82 1.39 0.31 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 24 24 24 23 23 22 22 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 332 311 299 349 656 658 656 1,012
Total Preferred & Common Equity		 332 311 299 349 656 658 656 1,012
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 332 311 299 349 656 658 656 1,012
Common Stock		 428 440 446 507 840 849 866 1,270
Retained Earnings		 -94 -128 -145 -157 -184 -189 -218 -261
Accumulated Other Comprehensive Income / (Loss)		 -2.28 -0.74 -1.06 -1.18 -0.52 -1.62 7.83 3.76

Annual Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 136.79% -6.14% 30.99%
EBITDA Growth		 0.00% -287.82% -107.45% -15.02% -36.41%
EBIT Growth		 0.00% -286.54% -103.74% -8.78% -35.45%
NOPAT Growth		 0.00% -579.93% -103.74% -8.78% -35.45%
Net Income Growth		 0.00% -381.60% -93.01% 7.56% -18.36%
EPS Growth		 0.00% 81.24% -9.35% 13.16% 3.03%
Operating Cash Flow Growth		 0.00% -288.56% -152.84% -17.83% 13.37%
Free Cash Flow Firm Growth		 0.00% 0.00% -223.67% -16.94% -15.25%
Invested Capital Growth		 0.00% -944.50% 27.34% 105.11% -845.17%
Revenue Q/Q Growth		 0.00% 0.00% 16.65% -4.54% -18.86%
EBITDA Q/Q Growth		 0.00% 0.00% -9.04% 1.86% -14.71%
EBIT Q/Q Growth		 0.00% 0.00% -7.66% 2.83% -14.99%
NOPAT Q/Q Growth		 0.00% 0.00% -7.66% 2.83% -14.99%
Net Income Q/Q Growth		 0.00% 0.00% -4.39% 6.88% -13.97%
EPS Q/Q Growth		 0.00% 0.00% -461.90% 10.81% -11.30%
Operating Cash Flow Q/Q Growth		 0.00% -108.96% -3.45% 3.83% -18.45%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.33% -12.66%
Invested Capital Q/Q Growth		 0.00% 0.00% 13.40% 142.02% -24.13%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -907.01% -794.62% -973.80% -1,014.09%
Operating Margin		 0.00% -905.39% -779.04% -902.87% -933.58%
EBIT Margin		 0.00% -905.39% -779.04% -902.87% -933.58%
Profit (Net Income) Margin		 0.00% -898.32% -732.22% -721.18% -651.62%
Tax Burden Percent		 77.75% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 102.42% 99.22% 93.99% 79.88% 69.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -97.11% -17.50% -18.36% -17.53% -10.09%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -17,969.56% 0.00%
Operating Return on Assets (OROA)		 0.00% -16.63% -18.04% -19.61% -13.71%
Return on Assets (ROA)		 0.00% -16.50% -16.96% -15.66% -9.57%
Return on Common Equity (ROCE)		 203.47% -16.49% -18.36% -17.53% -10.09%
Return on Equity Simple (ROE_SIMPLE)		 46.35% -8.92% -19.66% -16.93% -6.75%
Net Operating Profit after Tax (NOPAT)		 -3.39 -23 -47 -51 -69
NOPAT Margin		 0.00% -633.77% -545.33% -632.01% -653.50%
Net Nonoperating Expense Percent (NNEP)		 -43.44% -5.03% -4.59% -2.15% 0.03%
Return On Investment Capital (ROIC_SIMPLE)		 - - -14.64% -14.84% -6.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 284.00% 258.50% 323.39% 387.67%
R&D to Revenue		 0.00% 721.39% 620.54% 679.48% 645.90%
Operating Expenses to Revenue		 0.00% 1,005.39% 879.04% 1,002.87% 1,033.58%
Earnings before Interest and Taxes (EBIT)		 -8.52 -33 -67 -73 -99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.51 -33 -68 -79 -107
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 2.24 1.71 1.44 2.75
Price to Tangible Book Value (P/TBV)		 0.00 2.24 1.71 1.44 2.75
Price to Revenue (P/Rev)		 0.00 225.73 63.71 61.29 265.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 471.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 122.64 25.74 18.73 168.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.03 -1.02 -1.01 -1.00
Leverage Ratio		 2.32 1.06 1.08 1.12 1.05
Compound Leverage Factor		 2.38 1.05 1.02 0.89 0.74
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 309.53% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -209.53% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.54 37.20 7.64 8.07 44.06
Noncontrolling Interest Sharing Ratio		 309.53% 5.79% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 5.05 29.46 20.14 26.80 59.21
Quick Ratio		 4.97 29.30 19.81 26.40 58.72
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -15 -49 -58 -66
Operating Cash Flow to CapEx		 0.00% -1,145.48% -665.97% -2,733.78% -12,204.46%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -21.21 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -21.21 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.02 0.02 0.02 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 4.64 2.03 1.15 1.78
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -0.83 -8.64 -6.28 0.32 -2.39
Invested Capital Turnover		 0.00 -0.77 -1.15 -2.71 -10.23
Increase / (Decrease) in Invested Capital		 0.00 -7.81 2.36 6.60 -2.71
Enterprise Value (EV)		 208 446 222 151 1,785
Market Capitalization		 194 821 549 495 2,810
Book Value per Share		 ($16.00) $8.80 $7.70 $7.46 $19.49
Tangible Book Value per Share		 ($16.00) $8.80 $7.70 $7.46 $19.49
Total Capital		 6.99 366 321 344 1,023
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -7.81 -375 -327 -344 -1,025
Capital Expenditures (CapEx)		 0.00 1.48 6.45 1.85 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5.07 -11 -11 -7.82 -8.97
Debt-free Net Working Capital (DFNWC)		 13 364 316 336 1,016
Net Working Capital (NWC)		 13 364 316 336 1,016
Net Nonoperating Expense (NNE)		 3.39 9.62 16 7.21 -0.20
Net Nonoperating Obligations (NNO)		 -7.81 -375 -327 -344 -1,025
Total Depreciation and Amortization (D&A)		 0.01 -0.06 -1.34 -5.73 -8.53
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -295.38% -128.70% -96.75% -84.68%
Debt-free Net Working Capital to Revenue		 0.00% 10,014.35% 3,668.51% 4,159.45% 9,597.72%
Net Working Capital to Revenue		 0.00% 10,014.35% 3,668.51% 4,159.45% 9,597.72%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.39) ($1.52) ($1.32) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.62M 41.47M 44.02M 53.75M
Adjusted Diluted Earnings per Share		 $0.00 ($1.39) ($1.52) ($1.32) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.62M 41.47M 44.02M 53.75M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.39) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 23.53M 41.83M 51.66M 59.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.39 -23 -47 -51 -69
Normalized NOPAT Margin		 0.00% -633.77% -545.33% -632.01% -653.50%
Pre Tax Income Margin		 0.00% -898.32% -732.22% -721.18% -651.62%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -41.35 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -16.46 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -41.35 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -16.46 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 56.43% 76.05% 28.89% -55.31% 38.83% -13.50% -38.87% 741.72% -82.56% 0.00% -100.00%
EBITDA Growth		 -69.25% -42.06% -61.06% -28.21% 6.04% 7.77% 0.42% 26.35% -119.45% -77.94% -80.23%
EBIT Growth		 -65.29% -35.40% -51.24% -20.20% 12.26% 11.66% 0.59% 33.38% -126.66% -79.85% -73.09%
NOPAT Growth		 -65.29% -35.40% -49.76% -20.20% 12.26% 11.66% 0.59% 33.38% -126.66% -79.85% -73.09%
Net Income Growth		 -55.08% -19.75% -30.19% -3.67% 30.71% 26.81% 15.46% 65.96% -142.56% -71.93% -59.27%
EPS Growth		 -53.85% -125.16% -31.25% -2.44% 37.50% 41.03% 28.57% 73.81% -104.00% -56.52% -26.67%
Operating Cash Flow Growth		 -129.14% -13.66% -20.73% -147.88% 12.71% 16.89% -6.66% 33.43% 80.95% -68.92% -14.74%
Free Cash Flow Firm Growth		 -616.03% 0.00% -309.54% -92.58% -8.85% -18.12% -63.39% -17.44% -36.32% 1.62% 20.96%
Invested Capital Growth		 32.63% 27.34% 5.44% 63.56% 89.46% 105.11% 171.29% 398.01% -152.23% -845.17% -141.93%
Revenue Q/Q Growth		 -23.34% 56.92% -28.01% -48.39% 138.13% -2.22% -49.13% 610.62% -95.07% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.47% -3.31% -12.27% -2.85% 21.24% -1.41% -21.22% 23.94% -134.70% 17.77% -22.78%
EBIT Q/Q Growth		 -4.41% -1.35% -11.03% -2.30% 23.79% -2.05% -24.94% 31.44% -159.31% 19.03% -20.24%
NOPAT Q/Q Growth		 -4.41% -1.35% -11.03% -2.30% 23.79% -2.05% -24.94% 31.44% -159.31% 19.03% -20.24%
Net Income Q/Q Growth		 1.14% 3.78% -8.68% -0.28% 33.93% -1.64% -25.53% 59.63% -370.87% 27.95% -16.28%
EPS Q/Q Growth		 2.44% 2.50% -7.69% 0.00% 40.48% 8.00% -30.43% 63.33% -363.64% 29.41% -5.56%
Operating Cash Flow Q/Q Growth		 -120.88% 11.19% -16.77% -8.22% 22.22% 15.44% -49.85% 32.46% 77.74% -649.66% -1.79%
Free Cash Flow Firm Q/Q Growth		 -46.59% 6.06% 4.15% -45.91% 17.15% -1.94% -32.59% -4.87% 3.83% 26.43% -6.52%
Invested Capital Q/Q Growth		 30.86% 13.40% 10.60% 31.92% 80.00% 142.02% 1,146.11% 184.60% -116.93% -24.13% 29.89%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -1,022.67% -673.29% -1,050.10% -2,092.53% -692.13% -717.88% -1,710.54% -183.08% -8,708.43% 0.00% 0.00%
Operating Margin		 -994.04% -642.04% -990.28% -1,962.91% -628.25% -655.71% -1,610.30% -155.36% -8,164.46% 0.00% 0.00%
EBIT Margin		 -994.04% -642.04% -990.28% -1,962.91% -628.25% -655.71% -1,610.30% -155.36% -8,164.46% 0.00% 0.00%
Profit (Net Income) Margin		 -920.90% -564.67% -852.49% -1,656.39% -459.59% -477.77% -1,178.91% -66.98% -6,391.57% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.19% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.64% 88.67% 86.09% 84.38% 73.16% 72.86% 73.21% 43.11% 78.29% 69.66% 67.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -434.97% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -435.75% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 432.31% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17.06% -18.36% -20.11% -21.06% -18.40% -17.53% -11.50% -2.66% -12.05% -10.09% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -17,969.56% -1,515.31% -538.98% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -19.14% -14.87% -24.90% -41.93% -13.95% -14.24% -22.52% -4.55% -196.95% 0.00% 0.00%
Return on Assets (ROA)		 -17.73% -13.08% -21.43% -35.38% -10.21% -10.38% -16.49% -1.96% -154.18% 0.00% 0.00%
Return on Common Equity (ROCE)		 -17.06% -18.36% -20.11% -21.06% -18.40% -17.53% -11.50% -2.66% -12.05% -10.09% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -18.22% 0.00% -21.56% -22.62% -17.94% 0.00% -8.48% -6.70% -9.23% 0.00% -7.68%
Net Operating Profit after Tax (NOPAT)		 -13 -13 -14 -15 -11 -11 -14 -9.68 -25 -20 -24
NOPAT Margin		 -695.83% -449.43% -693.20% -1,374.04% -439.77% -459.00% -1,127.21% -108.75% -5,715.13% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.12% -0.93% -0.96% -0.91% -0.14% -0.14% -0.13% 0.78% -0.59% 0.01% 0.11%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.99% - - - -3.28% - - - -1.99% -2.41%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 336.35% 199.54% 315.63% 650.99% 255.78% 258.31% 586.50% 87.91% 4,024.37% 0.00% 0.00%
R&D to Revenue		 757.69% 542.50% 774.66% 1,411.92% 472.47% 497.40% 1,123.80% 167.45% 4,240.09% 0.00% 0.00%
Operating Expenses to Revenue		 1,094.04% 742.04% 1,090.28% 2,062.91% 728.25% 755.71% 1,710.30% 255.36% 8,264.46% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -18 -20 -21 -16 -16 -20 -14 -36 -29 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -19 -22 -22 -17 -18 -21 -16 -38 -31 -39
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.70 1.71 1.63 1.66 1.33 1.44 2.97 3.30 3.61 2.75 1.58
Price to Tangible Book Value (P/TBV)		 1.70 1.71 1.63 1.66 1.33 1.44 2.97 3.30 3.61 2.75 1.58
Price to Revenue (P/Rev)		 76.41 63.71 55.80 63.97 54.93 61.29 266.91 143.59 181.61 265.38 170.93
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 471.52 323.31 134.02 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 30.52 25.74 20.87 24.90 13.63 18.73 177.47 100.86 131.18 168.56 62.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.02 -1.02 -1.02 -1.01 -1.01 -1.00 -0.99 -1.00 -1.00 -1.00
Leverage Ratio		 1.08 1.08 1.08 1.13 1.12 1.12 1.08 1.08 1.08 1.05 1.04
Compound Leverage Factor		 1.00 0.96 0.93 0.95 0.82 0.82 0.79 0.47 0.84 0.73 0.70
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.21 8.08 7.65 7.34 7.74 8.56 35.80 39.33 37.07 44.28 25.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.08 20.14 19.95 17.28 24.55 26.80 62.09 57.34 38.80 59.21 58.47
Quick Ratio		 20.77 19.81 19.71 16.94 24.17 26.40 61.48 56.63 38.32 58.72 57.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -15 -15 -21 -18 -18 -24 -25 -24 -18 -19
Operating Cash Flow to CapEx		 -532.30% -579.43% -4,881.05% -2,595.52% -2,491.28% -1,922.52% -7,531.47% -10,548.42% -8,924.00% -39,821.43% -4,588.68%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.03 0.02 0.02 0.02 0.01 0.03 0.02 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 11.48 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.93 2.03 1.84 1.43 1.22 1.15 1.06 2.27 2.06 1.78 1.63
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 31.78 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 31.78 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.25 -6.28 -5.61 -3.82 -0.76 0.32 4.00 11 -1.93 -2.39 -1.68
Invested Capital Turnover		 -0.82 -1.15 -1.57 -1.09 -2.11 -2.71 -9.05 4.00 -9.70 -10.23 8.04
Increase / (Decrease) in Invested Capital		 3.51 2.36 0.32 6.66 6.48 6.60 9.61 15 -1.16 -2.71 -5.68
Enterprise Value (EV)		 225 222 189 193 115 151 1,293 1,526 1,712 1,785 582
Market Capitalization		 564 549 506 497 465 495 1,945 2,172 2,370 2,810 1,596
Book Value per Share		 $7.96 $7.70 $7.44 $7.16 $7.56 $7.46 $12.69 $12.68 $12.58 $19.49 $17.13
Tangible Book Value per Share		 $7.96 $7.70 $7.44 $7.16 $7.56 $7.46 $12.69 $12.68 $12.58 $19.49 $17.13
Total Capital		 332 321 311 299 349 344 656 658 656 1,023 1,012
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -339 -327 -317 -303 -350 -344 -652 -646 -658 -1,025 -1,014
Capital Expenditures (CapEx)		 2.52 2.06 0.29 0.58 0.47 0.52 0.20 0.10 0.03 0.04 0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -11 -12 -12 -8.99 -7.82 -3.71 4.10 -8.88 -8.97 -8.31
Debt-free Net Working Capital (DFNWC)		 328 316 305 291 341 336 648 650 649 1,016 1,006
Net Working Capital (NWC)		 328 316 305 291 341 336 648 650 649 1,016 1,006
Net Nonoperating Expense (NNE)		 4.08 3.28 3.26 2.98 0.50 0.46 0.65 -3.72 2.97 -0.10 -0.92
Net Nonoperating Obligations (NNO)		 -339 -327 -317 -303 -350 -344 -652 -646 -658 -1,025 -1,014
Total Depreciation and Amortization (D&A)		 -0.52 -0.89 -1.23 -1.37 -1.61 -1.53 -1.26 -2.47 -2.39 -2.42 -3.70
Debt-free, Cash-free Net Working Capital to Revenue		 -145.81% -128.70% -127.77% -153.18% -106.15% -96.75% -50.86% 27.11% -68.07% -84.68% -89.00%
Debt-free Net Working Capital to Revenue		 4,442.57% 3,668.51% 3,365.51% 3,753.68% 4,024.14% 4,159.45% 8,893.33% 4,299.56% 4,974.70% 9,597.72% 10,773.75%
Net Working Capital to Revenue		 4,442.57% 3,668.51% 3,365.51% 3,753.68% 4,024.14% 4,159.45% 8,893.33% 4,299.56% 4,974.70% 9,597.72% 10,773.75%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.40) ($0.39) ($0.42) ($0.42) ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 41.53M 41.47M 41.76M 41.84M 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M
Adjusted Diluted Earnings per Share		 ($0.40) ($0.39) ($0.42) ($0.42) ($0.25) ($0.23) ($0.30) ($0.11) ($0.51) ($0.36) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 41.53M 41.47M 41.76M 41.84M 45.71M 44.02M 49.05M 54.45M 54.63M 53.75M 61.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.66M 41.83M 41.83M 46.14M 46.17M 51.66M 51.85M 52.16M 52.48M 59.11M 59.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -13 -14 -15 -11 -11 -14 -9.68 -25 -20 -24
Normalized NOPAT Margin		 -695.83% -449.43% -693.20% -1,374.04% -439.77% -459.00% -1,127.21% -108.75% -5,715.13% 0.00% 0.00%
Pre Tax Income Margin		 -920.90% -569.31% -852.49% -1,656.39% -459.59% -477.77% -1,178.91% -66.98% -6,391.57% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Janux Therapeutics' Financials

When does Janux Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Janux Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Janux Therapeutics' net income changed over the last 4 years?

Janux Therapeutics' net income appears to be on an upward trend, with a most recent value of -$68.99 million in 2024, rising from -$6.78 million in 2020. The previous period was -$58.29 million in 2023. View Janux Therapeutics' forecast to see where analysts expect Janux Therapeutics to go next.

What is Janux Therapeutics' operating income?
Janux Therapeutics' total operating income in 2024 was -$98.85 million, based on the following breakdown:
  • Total Gross Profit: $10.59 million
  • Total Operating Expenses: $109.44 million
How has Janux Therapeutics' revenue changed over the last 4 years?

Over the last 4 years, Janux Therapeutics' total revenue changed from $0.00 in 2020 to $10.59 million in 2024, a change of 1,058,800,000.0%.

How much debt does Janux Therapeutics have?

Janux Therapeutics' total liabilities were at $38.74 million at the end of 2024, a 7.4% increase from 2023, and a 319.6% increase since 2020.

How much cash does Janux Therapeutics have?

In the past 4 years, Janux Therapeutics' cash and equivalents has ranged from $7.81 million in 2020 to $430.61 million in 2024, and is currently $430.61 million as of their latest financial filing in 2024.

How has Janux Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Janux Therapeutics' book value per share changed from -16.00 in 2020 to 19.49 in 2024, a change of -221.8%.


Related Companies

This page (NASDAQ:JANX) was last updated on 8/19/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel